RT Journal Article
T1 Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO)
A1 Puente, Javier
A1 González-del-Alba, Aranzazu
A1 Sala-Gonzalez, Núria
A1 Méndez-Vidal, María José
A1 Pinto, Alvaro
A1 Rodríguez, Ángel
A1 Cuevas Sanz, José Miguel
A1 Muñoz del Toro, Jacobo Rodrigo
A1 Useros Rodríguez, Eduardo
A1 García García-Porrero, Ángela
A1 Vázquez, Sergio
K1 Metastatic castration-resistant prostate cancer
K1 Abiraterone Acetate
K1 Cabazitaxel
K1 Chemotherapy
K1 Sequence
K1 Drug therapy
K1 Prostatic neoplasms
K1 Acetato de abiraterona
K1 Quimioterapia
K1 Neoplasias de la próstata
AB Background: To describe the patterns of second-line treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel treatment in a Spanish population, to identify the factors associated with those patterns, and to compare the efficacy and safety of the treatments most frequently administered.Methods: Observational, prospective study conducted in patients with histologically or cytologically confirmed prostate adenocarcinoma; documented metastatic castration-resistant disease; progression after first-line, docetaxel-based chemotherapy with or without other agents.Results: Of the 150 patients recruited into the study, 100 patients were prescribed abiraterone acetate plus prednisone (AAP), 44 patients received cabazitaxel plus prednisone (CP), and 6 patients received other treatments. Age (odds ratio [OR] 1.06, 95% [confidence interval] CI 1.01 to 1.11) and not elevated lactate dehydrogenase (LDH) levels (OR 0.33, 95% CI 0.14 to 0.76) were independently associated with the administration of AAP. Treatment with AAP was associated with significantly longer clinical/radiographic progression-free survival (hazard ratio [HR] 0.57, 95% CI 0.38 to 0.85) and overall survival (OS; HR 0.40, 95% CI 0.21 to 0.76) compared to CP, while no significant differences between the treatments were found regarding biochemical progression-free survival (PFS; HR 0.78 [95% CI 0.49 to 1.24]). However, in a post-hoc Cox regression analysis adjusted for potential confounders there were not differences between AAP and CP in any of the time-to-event outcomes, including overall survival. We observed no new safety signals related to either regimen.Conclusion: Second-line AAP for patients with mCRPC is the most common treatment strategy after progression with a docetaxel-based regimen. When controlling for potential confounders, patients receiving this treatment showed no differences in PFS and OS in comparison to those receiving CP, although these latter results should be confirmed in randomized controlled trials.
PB BioMed Central
YR 2019
FD 2019-08-05
LK http://hdl.handle.net/10668/3130
UL http://hdl.handle.net/10668/3130
LA en
NO Puente J, González-del-Alba A, Sala-Gonzalez N, Méndez-Vidal MJ, Pinto A, Rodríguez A, et al. Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO). BMC Cancer. 2019;19(1):766.
DS RISalud
RD Apr 12, 2025